SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease (AD), there is abnormal accumulation of Aβ and tau proteins in the brain. There is an associated immunological response, but it is still unclear whether this is beneficial or harmful. Inflammation in AD, specifically in the form of microglial activation, has, for many years, been considered to contribute to disease progression. However, two types of evidence suggest that it may be appropriate to revise this view: first, the disappointing results of prospective clinical trials of anti‐inflammatory agents and, second, the observation that microglia can clear plaques in AD following Aβ immunization. Although Aβ immunization alters AD pathology, there is limited evidence so far of benefit to cognitive function. Immunization against microorganisms is almost always used as a method of disease prevention rather than to treat a disease process that has already started. In animal models, immunotherapy at an early age can protect against Aβ accumulation and it will be interesting to see if this can usefully be applied to humans to prevent AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 2×
“APOE molecules are lipid carriers (15) involved in the redistribution of cholesterol within the brain to maintain the structural and functional integrity of membranes and synapses (63).”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 2×
“Since the first APP transgenic mouse model (36), numerous animal models have been designed based on the different APP point mutations that can cause familial AD.”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“Evidence for several potential mechanisms by which Ab is normally eliminated from the brain has emerged, including (i) by cellular mechanisms involving microglia (85, 90); (ii) by enzymatic degradation (eg, neprilysin and insulin degrading enzyme) (54, 91); (iii) by transport across the blood–brain barrier mediated by…”
Background
Research works printed but not linked: 76
- Adams DO, 1992, The Macrophage, 73
- 10.1038/nm0204-117 · DOI
- 10.1016/S0197-4580(00)00124-X · DOI · Paper page
- 10.1097/01.WCB.0000090080.64176.44 · DOI
- 10.1016/j.nbd.2006.01.004 · DOI
- 10.1001/archneur.64.4.583 · DOI
- 10.1084/jem.188.3.431 · DOI · Paper page
- 10.1128/cdli.1.4.433-436.1994 · DOI · Paper page
- Chao CC, 1994, Transforming growth factor beta in Alzheimer's disease, Clin Diagn Lab Immunol, 1, 109, 10.1128/cdli.1.1.109-110.1994 · DOI
- 10.1194/jlr.R300010-JLR200 · DOI · Paper page
- 10.1016/0197-4580(96)00103-0 · DOI
- 10.1128/JVI.79.8.5174-5184.2005 · DOI
- Das P, 2003, Amyloid‐beta immunization effectively reduces amyloid deposition in FcRgamma‐/‐ knock‐out mice, J Neurosci, 23, 8532, 10.1523/JNEUROSCI.23-24-08532.2003 · DOI · Paper page
- 10.1034/j.1601-183X.2002.10302.x · DOI · Paper page
- 10.1212/WNL.57.5.801 · DOI · Paper page
- 10.1111/j.1750-3639.1998.tb00166.x · DOI · Paper page
- 10.1111/j.1750-3639.2004.tb00493.x · DOI · Paper page
- 10.1016/0304-3940(91)90490-K · DOI · Paper page
- 10.1016/0167-5699(95)80064-6 · DOI · Paper page
- 10.1016/0167-5699(83)90169-X · DOI · Paper page
- 10.1016/S0092-8674(02)01201-1 · DOI · Paper page
- 10.1038/nri978 · DOI · Paper page
- 10.1097/00005072-199503000-00014 · DOI · Paper page
- 10.1111/j.1750-3639.1998.tb00136.x · DOI · Paper page
- 10.1038/ncb1313 · DOI · Paper page
- 10.1016/0092-8674(93)90312-E · DOI · Paper page
- Hallgren HM, 1973, Lymphocyte phytohemagglutinin responsiveness, immunoglobulins and autoantibodies in aging humans, J Immunol, 111, 1101, 10.4049/jimmunol.111.4.1101 · DOI · Paper page
- 10.1126/science.1072994 · DOI · Paper page
- 10.1016/S0896-6273(03)00294-0 · DOI · Paper page
- 10.1111/j.1749-6632.1996.tb34420.x · DOI
- 10.1002/ana.1061 · DOI · Paper page
- 10.1007/BF00689569 · DOI
- 10.1007/BF00685368 · DOI
- 10.1038/72237 · DOI · Paper page
- 10.1016/0166-2236(96)10049-7 · DOI · Paper page
- 10.1097/00001756-199803090-00010 · DOI · Paper page
- 10.1523/JNEUROSCI.20-15-05709.2000 · DOI · Paper page
- Lombardo JA, 2003, Amyloid‐beta antibody treatment leads to rapid normalization of plaque‐induced neuritic alterations, J Neurosci, 23, 10879, 10.1523/JNEUROSCI.23-34-10879.2003 · DOI · Paper page
- 10.1016/S0165-5728(00)00459-8 · DOI · Paper page
- Masliah E, 1991, Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease, Am J Pathol, 138, 235
- 10.1016/S0197-0186(01)00046-8 · DOI
- 10.1212/01.WNL.0000148590.39911.DF · DOI · Paper page
- 10.1017/S0317167100029863 · DOI · Paper page
- 10.1016/S0197-4580(02)00157-4 · DOI
- Mirra SS, 2002, Greenfield's Neuropathology, 195
- 10.1074/jbc.M414176200 · DOI · Paper page
- 10.1038/35050116 · DOI · Paper page
- 10.1002/cne.903270110 · DOI · Paper page
- 10.1016/j.neurobiolaging.2004.05.010 · DOI · Paper page
- 10.1016/j.neurobiolaging.2003.11.001 · DOI
- 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.0.CO;2-G · doi:10.1002/1531-8249(200003)47:3<365::aid-ana13>3.0.co;2-g
- 10.1074/jbc.M608485200 · DOI · Paper page
- 10.1074/jbc.272.46.29390 · DOI · Paper page
- 10.2353/ajpath.2006.060269 · DOI · Paper page
- 10.1111/j.1749-6632.2000.tb05564.x · DOI · Paper page
- 10.1074/jbc.272.10.6641 · DOI · Paper page
- 10.1016/j.neurobiolaging.2004.02.011 · DOI
- 10.1016/0306-4522(93)90353-H · DOI
- 10.1073/pnas.89.21.10016 · DOI · Paper page
- 10.1016/S0140-6736(68)92893-6 · DOI · Paper page
- 10.1523/JNEUROSCI.1344-04.2004 · DOI
- 10.1096/fj.04-1517fje · DOI · Paper page
- 10.1016/j.neuron.2006.01.022 · DOI · Paper page
- 10.1073/pnas.93.1.452 · DOI · Paper page
- 10.1073/pnas.94.8.4109 · DOI · Paper page
- Streit WJ, 1998, CNS Injuries: Cellular Responses and Pharmacological Strategies, 81
- 10.1016/j.brainresrev.2004.12.013 · DOI · Paper page
- 10.1073/pnas.90.5.1977 · DOI · Paper page
- 10.1016/S0169-328X(00)00149-2 · DOI
- Terry RD, 1964, Ultrastructural studies in Alzheimer's presenile dementia, Am J Pathol, 44, 269
- 10.1097/00001756-199301000-00018 · DOI · Paper page
- 10.1046/j.1471-4159.1997.69010388.x · DOI · Paper page
- 10.1016/S0531-5565(02)00029-3 · DOI · Paper page
- 10.1016/S0002-9440(10)65616-7 · DOI · Paper page
- 10.1186/1742-2094-1-24 · DOI
- 10.1111/j.1365-2990.1994.tb00956.x · DOI · Paper page
Cited by
Classification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
Review: Activation patterns of microglia and their identification in the human brain
Boche, D., Perry, V. H., & Nicoll, J. A. R. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12011 · Cited by 912
Self-citationStreit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727
Deane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 548
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
Metadata
- Authors
- Boche, D., & Nicoll, J. A. R.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2008-01-31
- Volume
- 18
- Issue
- 2
- Pages
- 267-278
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W1850100528
- Cited by
- 104
- References
- 47
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain. https://app.cochat.ai/papers/10.1111/j.1750-3639.2008.00134.x
- The paper
- Boche, D., & Nicoll, J. A. R. (2008). SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain. Brain Pathology. https://doi.org/10.1111/j.1750-3639.2008.00134.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.